Renal function in patients with HIV starting therapy with tenofovir and either efavirenz, lopinavir or atazanavir
| Autor: | Jim, Young, Juliane, Schäfer, Christoph A, Fux, Hansjakob, Furrer, Enos, Bernasconi, Pietro, Vernazza, Alexandra, Calmy, Matthias, Cavassini, Rainer, Weber, Manuel, Battegay, Heiner C, Bucher, S, Yerly |
|---|---|
| Přispěvatelé: | University of Zurich, Young, Jim |
| Rok vydání: | 2012 |
| Předmět: |
Cyclopropanes
Male Ritonavir/adverse effects Pyridines Kidney/drug effects/physiopathology HIV Infections Pharmacology urologic and male genital diseases Kidney Glomerular Filtration Rate/drug effects HIV Protease Inhibitors/administration & dosage/adverse effects Lopinavir 10234 Clinic for Infectious Diseases chemistry.chemical_compound immune system diseases Immunology and Allergy Organophosphonates/adverse effects Lopinavir/adverse effects Reverse Transcriptase Inhibitors/administration & dosage/adverse effects ddc:616 Reverse-transcriptase inhibitor Drug Therapy Combination/adverse effects/methods virus diseases Middle Aged Infectious Diseases Treatment Outcome Alkynes 2723 Immunology and Allergy Reverse Transcriptase Inhibitors Drug Therapy Combination Female Oligopeptides medicine.drug Glomerular Filtration Rate Adult medicine.medical_specialty Efavirenz Immunology Atazanavir Sulfate Urology HIV Infections/drug therapy Organophosphonates Renal function 610 Medicine & health Acquired immunodeficiency syndrome (AIDS) medicine Adenine/adverse effects/analogs & derivatives Humans Tenofovir Pyridines/adverse effects 2403 Immunology Ritonavir business.industry Adenine Benzoxazines/adverse effects 2725 Infectious Diseases HIV Protease Inhibitors medicine.disease Atazanavir Benzoxazines chemistry business Oligopeptides/adverse effects |
| Zdroj: | AIDS, Vol. 26, No 5 (2012) pp. 567-75 |
| ISSN: | 1473-5571 0269-9370 |
| Popis: | Background: Tenofovir is associated with reduced renal function, but it is not clear whether there is a greater decline in renal function when tenofovir is co-administered with a boosted protease inhibitor rather than with a nonnucleoside reverse transcriptase inhibitor (NNRTI). Methods: We calculated the estimated glomerular filtration rate (eGFR) for patients in the Swiss HIV Cohort Study. We estimated the difference in eGFR over time between first therapies containing tenofovir and either the NNRTI efavirenz or the protease inhibitors lopinavir (LPV/r) or atazanavir (ATV/r), both boosted with ritonavir. Results: Patients on a first therapy of tenofovir co-administered with efavirenz (n ¼484), LPV/r (n ¼269) and ATV/r (n ¼187) were followed for a median of 1.7, 1.2 and 1.3 years, respectively. Relative to tenofovir and efavirenz, the estimated difference in eGFR for tenofovir and LPV/r was � 2.6ml/min per 1.73m 2 [95% confidence interval (CI) � 7.3 to 2.2) during the first 6 months of therapy, then followed by a difference of 0.0ml/min per 1.73m 2 (95% CI � 1.1 to 1.1) for each additional 6 months of therapy. Relative to tenofovir and efavirenz, the estimated difference in eGFR fortenofovirandATV/r was � 7.6ml/min per 1.73m 2 (95% CI � 11.8to � 3.4) duringthe first 6 months of therapy, then followed by a difference of � 0.5ml/min per 1.73m 2 (95% CI � 1.6 to 0.7) for each additional 6 months of therapy. Conclusion: Tenofovir with either boosted protease inhibitor leads to a greater initial decline in eGFR than tenofovir with efavirenz; this decline may be worse with ATV/r than with LPV/r. 2012 Wolters Kluwer Health | Lippincott Williams & Wilkins AIDS 2012, 26:567‐575 |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|